Prem Premsrirut

Prem Premsrirut is the current CEO and founder of Mirimus. Prior to this, Premsrirut worked as a PhD student at Cold Spring Harbor Laboratory from 2005 to 2010. There, they helped develop a high-throughput pipeline for the rapid production of conditional mouse models using RNA interference technology to regulate the expression of any endogenous gene. These models serve as invaluable basic research and preclinical tools that help identify new therapeutic targets and direct drug development for the treatment of human diseases. This thesis project resulted in a $2M contract between CSHL and the National Cancer Institute for development of 1500 models currently being held in a repository for academic researchers globally.

Premsrirut then went on to attend Stony Brook University Health Sciences Center School of Medicine from 2003 to 2016, where they studied to become a medical doctor. While there, they also researched tumor suppressor genes involved in tumor maintenance of Kras-induced lung adenocarcinoma in the laboratory of Dr. Scott W. Lowe. Their findings implicated a new of potential new drug targets including HDAC inhibitors to prevent chromatin silencing.

Prem Premsrirut has a background in entrepreneurship, business administration, and management. Prem earned their doctor of medicine from Stony Brook University, and their doctor of philosophy in genetics from Cold Spring Harbor Laboratory. Prem also holds a BA in biochemistry and molecular biology from UC Berkeley.

Sean Seibel - Chief Product & Technology Officer, Daniel Neumann - Head of Logistics, and Helen Hoxie - Lab Scientific Manager report to Prem Premsrirut.